New combo therapy aims to shrink liver tumors while preserving liver function

NCT ID NCT06632717

First seen Jan 05, 2026 · Last updated May 08, 2026 · Updated 20 times

Summary

This study tests a treatment for advanced liver cancer that delivers chemotherapy directly to the liver through a small tube, combined with a temporary blocking agent (lipiodol) to trap the drugs in the tumor. The goal is to shrink tumors while keeping the liver working well. About 24 adults with liver cancer that has spread or not responded to standard treatments will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Taiwan University Hospital

    RECRUITING

    Taipei, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.